ARCHIVES

Sole Source Negotiations

This article is from The Cancer Letter archive.

Vol. 01 No. 42 | October 17, 1975

Download PDF Visit The Full Archive

Related Articles

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

January 28, 1994

Cyclamate Committee Finds No Proof Of Carcinogenicity

January 23, 1976

Minority CCOP Applications Not Yet Reviewed

December 15, 1989

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

MEPACT Approved In Europe For Resectable Osteosarcoma

March 27, 2009

DePinho Seeks Broad Waiver From COI Policy To Cover Financial Ties With 12 Entities

September 21, 2012